ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1451

Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable In The United States

Siva Narayanan1, Yao Lu2, Richard Hutchings2 and Amanda Baskett2, 1Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, 2Ipsos Healthcare, London, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologic agents, Clinical Response, Disease Activity and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Data on clinical status of biologic-naïve Rheumatoid Arthritis (RA) patients who are considered suitable for biologic therapy (by their physicians) is lacking. We assessed clinical characteristics of RA patients who are considered suitable for biologic therapy (by their physicians) in comparison to those currently treated with 1stline biologics in the United States (US).

Methods:

A retrospective chart review study of RA patients was conducted among physicians (primarily rheumatologists) in hospitals/private practices to collect de-identified data on patients who were either recently treated with a biologic as part of usual care or considered suitable for biologic treatment. Physicians from the US were screened for duration of practice (3-30 yrs) and patient volume (incl. >2RA biologic patients/week) and recruited from a large panel to be geographically representative. Eligible patient charts (>6 biologic patients, > 2 biologic-suitable (and yet biologic-naïve) patients per physician judgment) were randomly selected from a sample of prospective patients visiting each center/practice during the screening period. Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient symptomatology/disease status. This retrospective de-identified data collection method met the criteria for IRB exemption under federal regulation 45 CFR 46.101(b)(4).

Results:

Seven hundred and twenty six eligible RA patient charts were abstracted; 378 (52%) patients were on their first biologic and 175 (24%) patients have never experienced biologic but were considered suitable for one. Mean age was: 1st line-52.8yrs, biologic-suitable-51.5yrs; Female: 1st line-73%, biologic-suitable-76%. Disease severity at diagnosis and current disease severity (both per physician judgment) (mild:moderate:severe) were: 1st line – 6%:74%:14% and 67%:29%:3%, biologic-suitable – 11%,74%, 10% and 25%:66%:9% respectively. Current drug class usage differed between the two groups (1st line/biologic-suitable): non-biological DMARD (57%/88%), steroids (19%/36%), NSAIDs-COX2 inhibitors (6%/10%), NSAIDs- non-COX2 inhibitors (14%/22%), and analgesics (11%/12%). Key lab measures documented were (1st line/biologic suitable): ESR (24.2/40.0 mm/h) and CRP (2.5mg/5.6 dl). Current ACR scores were (1st line/biologic-suitable):  no response (2%/19%), ACR20 (12%/36%), ACR50 (18%/15%), ACR70 (20%/5%), ACR90 (26%/1%). Among patients with available data, current HAQ (1st line – 0.7, biologic-suitable – 1.1), DAS28 (1st line – 2.5, biologic-suitable – 4.1), 100mmVAS (1st line – 2.3, biologic-suitable – 4.6), Swollen Joint Count (1st line – 2.0, biologic-suitable – 5.9) and Tender Joint Count (1st line – 2.8, biologic-suitable – 7.0) differed between the patient groups.

Conclusion:

Compared to the patients currently treated with 1st line biologic, RA biologic-naïve but suitable patients (per physician judgment) had relatively higher disease burden. Reasons for non-initiation of biologic treatment among ‘biologic-suitable’ patients warrant further investigation to alleviate disease burden.


Disclosure:

S. Narayanan,

Ipsos Healthcare,

3;

Y. Lu,

Ipsos Healthcare,

3;

R. Hutchings,

Ipsos Healthcare,

3;

A. Baskett,

Ipsos Healthcare,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-clinical-characteristics-of-patients-with-rheumatoid-arthritis-receiving-their-first-biologic-and-biologic-naive-patients-considered-biologic-suitable-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology